Immunitybio is trading at $7.12 (-4.43%) as the stock pulls back from its recent rally, tracking broader weakness across the biotechnology sector.
- The decline follows a significant +9.08% gain on July 30; with no new company-specific catalysts reported, the stock appears to be undergoing a natural correction.
- Sector-wide pressure is a primary driver for the move, with the XBI biotech index falling 3.15% during the current session.